Exentis.
Industrialized Additive Manufacturing
at its best.

Pharma & MedTech
New Energy
Ultra-fine Structures
Exentis offers a unique 3D technology platform for industrial large-scale production.
Become part of our 3D community!

Why Exentis?

Highest expertise in
additive manufacturing technology

Why Exentis?

Industrialized large-scale production with a free choice of materials

Why Exentis?

Production of millions of
ultra-fine components

Why Exentis?

Use of our 3D technology also in cleanroom
settings for pharmaceuticals and
bioprinting solutions

Why Exentis?

Leading 3D technology platform with comprehensive patent protection

Why Exentis?

Exclusive use of our 3D technology through
long-term license agreements
3D technology

Industrialized large-scale production with a free choice of materials

Production of millions of components per year using a single 3D system. Or up to 200 million tablets with freely definable release profiles for the active pharmaceutical ingredients.

Read more
Application examples

Our 3D technology can be used in many fields

We focus on the strategic business areas of Pharma & MedTech, New Energy and Ultra-fine Structures.

Read more
Sustainability

Sustainability is not just a buzzword for us

We view sustainability as an integral part of our corporate responsibility.

Read more
Career

Join our team!

You can expect exciting tasks, outstanding career opportunities and a team-oriented, supportive working atmosphere.

Read more
Trade fair activity

Visit us at our booths!

We would be pleased to welcome you personally at our booths.

Read more

Recent news

  • 31.08.2023
    High attention for Exentis at Formnext Forum Austin
    • Great interest in Exentis at Formnext Forum Austin, Texas
    • High demand for ultra-fine structured applications manufactured on Exentis’ Additive Technology Platform
    • Following the establishment of Exentis North America Inc., Exentis will consistently grow its footprint in the USA
  • 24.08.2023
    Profitable growth course continued in the first half of 2023
    • Group revenues increased by 15% to CHF 11.4 million, EBITDA margin improved to 18.7%
    • Three strategic initiatives being implemented to realize the market potential
    • Positive outlook for the full year 2023
  • 23.06.2023
    Exentis Group AG Annual General Meeting 2023
    • Shareholders approve the proposals of the Board with a large majority
    • Current Board confirmed, Albert F. Angehrn elected as new member
    • Articles of Incorporation adapted to new stock corporation law
All news

Exentis 3D community